UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 134

Sortiert nach

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

The New England journal of medicine, 2016-07, Vol.375 (4), p.345-356

2016

Link zum Volltext

Verfügbarkeit prüfen

Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)

Journal of the American Academy of Dermatology, 2015-07, Vol.73 (1), p.27-36.e1

2015

Link zum Volltext

Verfügbarkeit prüfen

Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis

Journal of the American Academy of Dermatology, 2016-07, Vol.75 (1), p.83-98.e4

2016

Link zum Volltext

Verfügbarkeit prüfen

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

Journal of the American Academy of Dermatology, 2015-07, Vol.73 (1), p.37-49

2015

Link zum Volltext

Verfügbarkeit prüfen

Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis

Journal of allergy and clinical immunology, 2014-04, Vol.133 (4), p.1032-1040

2014

Link zum Volltext

Verfügbarkeit prüfen

Guidelines of care for the management of psoriasis and psoriatic arthritis

Journal of the American Academy of Dermatology, 2011-07, Vol.65 (1), p.137-174

2011

Link zum Volltext

Verfügbarkeit prüfen

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

Journal of the American Academy of Dermatology, 2008, Vol.58 (1), p.106-115

2008

Link zum Volltext

Verfügbarkeit prüfen

A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis

Journal of the American Academy of Dermatology, 2014-12, Vol.71 (6), p.1176-1182

2014

Link zum Volltext

Verfügbarkeit prüfen

Humanized anti–IFN-γ (HuZAF) in the treatment of psoriasis

Journal of allergy and clinical immunology, 2015-02, Vol.135 (2), p.553-556.e3

2015

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis

Journal of the American Academy of Dermatology, 2010-09, Vol.63 (3), p.448-456

2010

Link zum Volltext

Verfügbarkeit prüfen

Research gaps in psoriasis: Opportunities for future studies

Journal of the American Academy of Dermatology, 2014-01, Vol.70 (1), p.146-167

2014

Link zum Volltext

Verfügbarkeit prüfen

Integrated safety analysis: Short- and long-term safety profiles of etanercept in patients with psoriasis

Journal of the American Academy of Dermatology, 2012-08, Vol.67 (2), p.245-256

2012

Link zum Volltext

Verfügbarkeit prüfen

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics

Journal of the American Academy of Dermatology, 2019-04, Vol.80 (4), p.1029-1072

2019

Link zum Volltext

Verfügbarkeit prüfen

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)

Journal of the American Academy of Dermatology, 2018-08, Vol.79 (2), p.302-314.e6

2018

Link zum Volltext

Verfügbarkeit prüfen

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities

Journal of the American Academy of Dermatology, 2019-04, Vol.80 (4), p.1073-1113

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial

JAMA dermatology (Chicago, Ill.), 2020-06, Vol.156 (6), p.649

2020

Link zum Volltext

Verfügbarkeit prüfen

Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies

Journal of the American Academy of Dermatology, 2020-06, Vol.82 (6), p.1445-1486

2020

Link zum Volltext

Verfügbarkeit prüfen

Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

JAMA dermatology (Chicago, Ill.), 2015-09, Vol.151 (9), p.961

2015

Link zum Volltext

Verfügbarkeit prüfen

Guidelines of care for the management of psoriasis and psoriatic arthritis Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics

Journal of the American Academy of Dermatology, 2008-05, Vol.58 (5), p.826-850

2008

Link zum Volltext

Verfügbarkeit prüfen

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions

Journal of the American Academy of Dermatology, 2011-07, Vol.65 (1), p.137-174

2011

Link zum Volltext

Verfügbarkeit prüfen

Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a

Seminars in cutaneous medicine and surgery, 2016-06, Vol.35 (4 Suppl 4), p.S74-S77

Leonardi, Craig L

2016

Link zum Volltext

Verfügbarkeit prüfen

Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a

Seminars in cutaneous medicine and surgery, 2016-06, Vol.35 (4S), p.S74

Leonardi, Craig L

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 134

Suche als RSS-Feed

Aktive Filter

KollektionTaylor & Francis:Master (3349 titles)

Zeitschrift / SerieDermatology And Therapy

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(121)
Mit Volltextzugriff
(97)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(83)
Dermatology
(82)
Humans
(82)
Life Sciences & Biomedicine
(80)
Psoriasis - Drug Therapy
(51)
Biological And Medical Sciences
(41)
Medical Sciences
(41)
Female
(40)
Male
(40)
Psoriasis
(40)
Middle Aged
(33)
Adult
(31)
Treatment Outcome
(27)
Severity Of Illness Index
(25)
Psoriasis. Parapsoriasis. Lichen
(24)
Antibodies, Monoclonal - Therapeutic Use
(20)
Aged
(18)
Antibodies, Monoclonal - Adverse Effects
(17)
Double-Blind Method
(17)
Antibodies, Monoclonal - Administration & Dosage
(16)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)

Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis

Guidelines of care for the management of psoriasis and psoriatic arthritis

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis

Humanized anti–IFN-γ (HuZAF) in the treatment of psoriasis

Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis

Research gaps in psoriasis: Opportunities for future studies

Integrated safety analysis: Short- and long-term safety profiles of etanercept in patients with psoriasis

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial

Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies

Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Joint AAD–NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures

Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy

Guidelines of care for the management of psoriasis and psoriatic arthritis Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics

Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions

Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a

Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a

Aktive Filter

Suchergebnisse filtern